Today, the most validated MRD-biomarkers remain cancer-specific antigens such as CA125, CA15.3, carcinogen embryonic antigen (CEA), alpha-feto protein (αFP), and prostate-specific antigen (PSA) [76]. This evidence concerns the gene AFP and cancer.